SEC Company Response from Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142) (WHWK) — Apr 9, 2018
Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142)
Date: April 9, 2018 · CIK: 0001422142 · Accession: 0001193125-18-111668
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223113
Letter
Acceleration request
Aerpio Pharmaceuticals, Inc.
9987 Carver Road
Cincinnati, OH 45242
April 9, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Aerpio Pharmaceuticals, Inc. (the “Company”)
Acceleration Request for Registration Statement on Form S-3
File No. 333-223113
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on April 11, 2018, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act.
Very truly yours,
Aerpio Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acceleration request Aerpio Pharmaceuticals, Inc. 9987 Carver Road Cincinnati, OH 45242 April 9, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aerpio Pharmaceuticals, Inc. (the “Company”) Acceleration Request for Registration Statement on Form S-3 File No. 333-223113 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on April 11, 2018, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act. Very truly yours, Aerpio Pharmaceuticals, Inc. By: /s/ Stephen Hoffman Name: Title: Stephen Hoffman Chief Executive Officer cc: Goodwin Procter LLP